Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PPBT 
Purple Biotech (PPBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PPBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $34
1 Year Target Price $34
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.65% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.15M USD | Price to earnings Ratio - | 1Y Target Price 34 |
Price to earnings Ratio - | 1Y Target Price 34 | ||
Volume (30-day avg) 1 | Beta -0.51 | 52 Weeks Range 0.53 - 8.40 | Updated Date 09/15/2025 |
52 Weeks Range 0.53 - 8.40 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -10.27% | Return on Equity (TTM) -8.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -381962 | Price to Sales(TTM) 58.08 |
Enterprise Value -381962 | Price to Sales(TTM) 58.08 | ||
Enterprise Value to Revenue 33.08 | Enterprise Value to EBITDA -0.15 | Shares Outstanding 9030450 | Shares Floating 503464447 |
Shares Outstanding 9030450 | Shares Floating 503464447 | ||
Percent Insiders 6.82 | Percent Institutions 4.1 |
Upturn AI SWOT
Purple Biotech
Company Overview
History and Background
Purple Biotech Ltd. (formerly Kitov Pharma) is a clinical-stage company focused on developing oncology therapies. Founded in 2010, they shifted focus to address resistance to cancer treatments.
Core Business Areas
- CM24: A monoclonal antibody targeting CEACAM1, currently in clinical development for solid tumors. It's designed to overcome cancer resistance.
- NT219: A small molecule that inhibits IRS1/2-mediated signaling, aiming to disrupt cancer survival pathways. It's being explored in various cancers.
Leadership and Structure
Dr. Gil Heldman is the CEO. The company operates with a scientific advisory board and a management team focused on clinical trials and drug development.
Top Products and Market Share
Key Offerings
- CM24: CM24 is in clinical development targeting solid tumors. Market share data is not yet applicable as it's not yet commercialized. Competitors include companies developing similar CEACAM1 inhibitors or alternative immuno-oncology approaches.
- NT219: NT219 is in clinical development targeting solid tumors. Market share data is not yet applicable as it's not yet commercialized. Competitors include companies developing inhibitors of the IRS1/2 pathway or other therapies targeting cancer cell survival.
Market Dynamics
Industry Overview
The oncology market is large and growing, with significant unmet needs, especially in overcoming drug resistance.
Positioning
Purple Biotech focuses on novel mechanisms to overcome resistance to cancer therapies, positioning them in a high-need segment.
Total Addressable Market (TAM)
The global oncology market is estimated to be hundreds of billions of dollars. Purple Biotech aims to capture a portion of this market by addressing drug resistance. TAM exceeds $100B, PBI is aiming to develop novel products and is in early stages of TAM capture.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets (CEACAM1, IRS1/2)
- Clinical-stage assets
- Experienced management team
Weaknesses
- Limited financial resources
- High risk of clinical trial failure
- Dependence on successful clinical development
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results
- Expansion into new indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failure
Competitors and Market Share
Key Competitors
Competitive Landscape
Purple Biotech competes with companies developing oncology therapies. Its advantage lies in its novel targets, but it faces intense competition and requires significant funding.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by clinical development progress. No significant revenue growth has been reported to date.
Future Projections: Future growth depends on successful clinical trials and potential partnerships. Analyst projections are highly variable.
Recent Initiatives: Focus on advancing CM24 and NT219 through clinical trials.
Summary
Purple Biotech is a clinical-stage company with novel oncology therapies. Its success hinges on positive clinical trial outcomes and securing partnerships. Limited financial resources and intense competition pose significant challenges. The company needs to demonstrate clinical efficacy to attract investment and achieve commercial success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on independent research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Purple Biotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://purple-biotech.com |
Full time employees 9 | Website https://purple-biotech.com | ||
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.